CLBS 14 - Caladrius Biosciences

Drug Profile

CLBS 14 - Caladrius Biosciences

Alternative Names: CD34+ cell therapy; CLBS14 - Caladrius Biosciences

Latest Information Update: 09 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Caladrius Biosciences
  • Class Cardiovascular therapies; Cell therapies
  • Mechanism of Action CD34-antigen-stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cardiovascular disorders

Most Recent Events

  • 02 Oct 2017 Caladrius Biosciences has patent protection for CLBS 14 in USA
  • 02 Oct 2017 Preclinical trials in Cardiovascular disorders in USA (Infusion) before October 2017
  • 02 Oct 2017 Caladrius Biosciences plans a phase II trial for Coronary microvascular dysfunction in USA in early 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top